Oncotarget

Research Papers: Immunology:

Urine anti-PLA2R antibody is a novel biomarker of idiopathic membranous nephropathy

Yu Wang, Yi-Xin He, Tian-Tian Diao, Shi-Yao Wei, Wen-Rui Qi, Cen-Cen Wang, Shu-Min Song, Min Bi, Chun-Mei Li, Cai-Xia Zhang, Yan-Pei Hou, Qiu-Ju Wei and Bing Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:67-74. https://doi.org/10.18632/oncotarget.19859

Metrics: PDF 1790 views  |   HTML 2828 views  |   ?  


Abstract

Yu Wang1, Yi-Xin He1, Tian-Tian Diao1, Shi-Yao Wei1, Wen-Rui Qi2, Cen-Cen Wang1, Shu-Min Song1, Min Bi1, Chun-Mei Li1, Cai-Xia Zhang1, Yan-Pei Hou1, Qiu-Ju Wei1 and Bing Li1

1 Department of Nephrology, Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China

2 Science and Technology Department, Financial Mathematics Major, Beijing Normal University, Hong Kong Baptist University United International College, Zhuhai, People’s Republic of China

Correspondence to:

Bing Li, email:

Keywords: idiopathic membranous nephropathy, urine anti-PLA2R antibody, proteinuria, biomarker, diagnosis, Immunology

Received: May 02, 2017 Accepted: July 25, 2017 Published: August 03, 2017

Abstract

Since urine samples more directly reflect kidney alterations and damage than blood samples, we investigated whether urine anti-PLA2R antibody (uPLA2R-Ab) could be utilized similarly to serum anti-PLA2R antibody (sPLA2R-Ab) as a noninvasive biomarker of idiopathic membranous nephropathy (IMN). In this study, we performed a qualitative analysis using an indirect immunofluorescence test (IIFT) and measured uPLA2R-Ab and sPLA2R-Ab concentrations using an enzyme-linked immunosorbent assay (ELISA) in 28 patients with biopsy-proven IMN and 12 patients with secondary membranous nephropathy (SMN). Overall, 64.3% (n=18) of patients with IMN had IIFT-positive sPLA2R-Ab, 67.9% (n=19) of patients with IMN had IIFT-positive uPLA2R-Ab, and none of the SMN patients had IIFT-positive sPLA2R-Ab or uPLA2R-Ab. The titers of the anti-PLA2R antibody from the IMN patients in the urine (10.72±22.24 RU/μmol, presented as uPLA2R-Ab/urine creatinine) and serum (107.36±140.93 RU/ml) were higher than those from the SMN patients (0.51±0.46 RU/μmol, 0.008±0.029 RU/ml, respectively, p<0.05). Statistical analyses indicated that there were positive correlations between uPLA2R-Ab and gPLA2R, sPLA2R-Ab or urinary protein and negative correlations between uPLA2R-Ab and serum albumin in patients with IMN. In conclusion, uPLA2R-Ab is a novel biomarker of IMN. sPLA2R-Ab combined with uPLA2R-Ab might be more helpful for diagnosis and activity in PLA2R associated MN.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19859